Ticker: RMD
ResMed
Healthcare
Healthcare
Medical - Instruments & Supplies
Price
195.27
Reco
Sell
Potential
34
Risk
75
Updated
2026-07-27
Forecast impact
Target
+53.6%
target fill 65.1%
Reaction
D5 pending · D10 pending
market trust
Impact
Potential -4 · Risk +3
valid until 2026-08-20
Track in portfolio
Price chart
AI recommendation
Analyst forecast
Calendar event
Positive signal
Negative signal
Neutral / update
Hold / informational
B My buy
S My sell
Description
Company and Business Model
ResMed is a healthcare company specializing in cloud-connected devices and software solutions for people with sleep apnea and chronic obstructive pulmonary disease (COPD). Its core products include continuous positive airway pressure (CPAP) devices, masks, and cloud-based software for patient management. The company operates primarily in the sleep and respiratory care segments, with major revenue sources stemming from device sales, software subscriptions, and related accessories.
Investment Profile
The investment profile of ResMed is more aligned with balanced investors, given its moderate growth potential and dividend yield. The company offers a steady revenue stream while also providing some income through dividends. However, the elevated risk factors suggest caution for those seeking aggressive growth.
Category: Healthcare
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Investment style: Growth
Horizon: Medium-term
Company type: Blue Chip
Company type: Market Leader
Fundamental metrics (experimental) Updated: 2026-07-26
- EPS (TTM) — earnings per share for the last 12 months, $
- 10.38
- Revenue QoQ — quarter-over-quarter revenue growth
- 0.6%
- EPS surprise
- 2.5%
- 20d volatility
- 2.5%
- Dividend yield
- 1.2%
- last ex-date
- 2026-05-14
AI recommendation changes
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-12 | Hold | Sell | Weak momentum and high risk; cautious outlook advised. |
| 2026-06-27 | Sell | Hold | Positive short-term momentum, but long-term risks persist. |
| 2026-06-03 | Hold | Sell | Weak momentum and high risk overshadow potential upside. |
| 2026-05-24 | Sell | Hold | Weak momentum and mixed fundamentals suggest caution. |
| 2026-05-08 | — | Sell | Weak momentum and high risk overshadow potential upside. |
| 2026-05-08 | Hold | Sell | Компания демонстрирует отрицательную динамику акций за последние месяцы, что указывает на высокие риски. Однако стабильный EPS и дивидендная доходность могут привлечь долгосрочных инвесторов. |
| 2026-03-09 | Buy | Hold | Компания показывает умеренный рост выручки, но последние месяцы наблюдается снижение цены акций. Рекомендуется удерживать позицию до более ясных сигналов о восстановлении. |
| 2026-02-26 | Hold | Buy | Компания показывает умеренный рост выручки и стабильную прибыль, однако недавние колебания цен и снижение на более длительных интервалах вызывают осторожность. Рекомендуется удерживать акции до более ясных сигналов о вос |
| 2026-02-18 | Buy | Hold | Компания показывает умеренный рост выручки и стабильные показатели прибыли, однако недавнее снижение цен на акции и волатильность на рынке указывают на определенные риски. |
| 2026-02-08 | Hold | Buy | Компания ResMed демонстрирует положительную динамику цен за последние 20 и 60 дней, что указывает на рост интереса инвесторов. Несмотря на некоторые колебания в более длительном периоде, текущие тренды и потенциал сектор |
Analyst forecasts
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-07-21 | UBS | Target Lowered | — → 300 | 195.97 |
| 2026-07-16 | RBC Capital | Rating Downgraded | — → 234 | 198.57 |
| 2026-07-15 | Mizuho Securities | Target Lowered | 235 → 220 | 193.01 |
| 2026-07-10 | Jefferies | Target Lowered | 240 → 225 | 204.5 |
| 2026-07-08 | RBC Capital | Target Lowered | 321 → 276 | 219.75 |
| 2026-07-08 | Wells Fargo | Target Lowered | 227 → 225 | 219.75 |
| 2026-06-22 | KeyBanc | Target Lowered | 290 → 266 | 188.63 |
| 2026-06-17 | Morgan Stanley | Update | — → 230 | 193.94 |
| 2026-05-01 | Robert W. Baird | Target Lowered | 254 → 225 | 203.87 |
| 2026-04-27 | KeyBanc | Target Lowered | 302 → 290 | 219.85 |
| 2026-04-13 | Evercore ISI | Target Lowered | 300 → 255 | 228.33 |
| 2026-01-30 | RBC Capital | Target Raised | 311 → 314 | 254.08 |
| 2026-01-30 | Stifel Nicolaus | Target Raised | 260 → 265 | 257.61 |
| 2026-01-30 | KeyBanc | Target Raised | 299 → 302 | 257.61 |
| 2026-01-30 | Robert W. Baird | Target Raised | 275 → 281 | 257.61 |
| 2026-01-30 | Piper Sandler | Target Raised | 270 → 275 | 257.61 |
| 2025-12-18 | Stifel Nicolaus | Target Lowered | — → 260 | 245.94 |
| 2025-12-16 | Robert W. Baird | Rating Downgraded | — → 275 | 253.07001 |
News Page 1 of 1
Nothing yet